Repurposing of Tibolone in Alzheimer’s Disease
Alzheimer’s disease (AD) is a debilitating neurodegenerative disease characterised by the accumulation of amyloid-beta and tau in the brain, leading to the progressive loss of memory and cognition. The causes of its pathogenesis are still not fully understood, but some risk factors, such as age, gen...
| Main Author: | |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
MDPI AG
2023-07-01
|
| Series: | Biomolecules |
| Subjects: | |
| Online Access: | https://www.mdpi.com/2218-273X/13/7/1115 |
| _version_ | 1797590113414283264 |
|---|---|
| author | George E. Barreto |
| author_facet | George E. Barreto |
| author_sort | George E. Barreto |
| collection | DOAJ |
| description | Alzheimer’s disease (AD) is a debilitating neurodegenerative disease characterised by the accumulation of amyloid-beta and tau in the brain, leading to the progressive loss of memory and cognition. The causes of its pathogenesis are still not fully understood, but some risk factors, such as age, genetics, and hormones, may play a crucial role. Studies show that postmenopausal women have a higher risk of developing AD, possibly due to the decrease in hormone levels, especially oestrogen, which may be directly related to a reduction in the activity of oestrogen receptors, especially beta (ERβ), which favours a more hostile cellular environment, leading to mitochondrial dysfunction, mainly affecting key processes related to transport, metabolism, and oxidative phosphorylation. Given the influence of hormones on biological processes at the mitochondrial level, hormone therapies are of clinical interest to reduce the risk or delay the onset of symptoms associated with AD. One drug with such potential is tibolone, which is used in clinics to treat menopause-related symptoms. It can reduce amyloid burden and have benefits on mitochondrial integrity and dynamics. Many of its protective effects are mediated through steroid receptors and may also be related to neuroglobin, whose elevated levels have been shown to protect against neurological diseases. Its importance has increased exponentially due to its implication in the pathogenesis of AD. In this review, we discuss recent advances in tibolone, focusing on its mitochondrial-protective effects, and highlight how valuable this compound could be as a therapeutic alternative to mitigate the molecular pathways characteristic of AD. |
| first_indexed | 2024-03-11T01:15:48Z |
| format | Article |
| id | doaj.art-9d7d1a7ebb3d41bfa3a890e30b07f60a |
| institution | Directory Open Access Journal |
| issn | 2218-273X |
| language | English |
| last_indexed | 2024-03-11T01:15:48Z |
| publishDate | 2023-07-01 |
| publisher | MDPI AG |
| record_format | Article |
| series | Biomolecules |
| spelling | doaj.art-9d7d1a7ebb3d41bfa3a890e30b07f60a2023-11-18T18:31:38ZengMDPI AGBiomolecules2218-273X2023-07-01137111510.3390/biom13071115Repurposing of Tibolone in Alzheimer’s DiseaseGeorge E. Barreto0Department of Biological Sciences, University of Limerick, V94 T9PX Limerick, IrelandAlzheimer’s disease (AD) is a debilitating neurodegenerative disease characterised by the accumulation of amyloid-beta and tau in the brain, leading to the progressive loss of memory and cognition. The causes of its pathogenesis are still not fully understood, but some risk factors, such as age, genetics, and hormones, may play a crucial role. Studies show that postmenopausal women have a higher risk of developing AD, possibly due to the decrease in hormone levels, especially oestrogen, which may be directly related to a reduction in the activity of oestrogen receptors, especially beta (ERβ), which favours a more hostile cellular environment, leading to mitochondrial dysfunction, mainly affecting key processes related to transport, metabolism, and oxidative phosphorylation. Given the influence of hormones on biological processes at the mitochondrial level, hormone therapies are of clinical interest to reduce the risk or delay the onset of symptoms associated with AD. One drug with such potential is tibolone, which is used in clinics to treat menopause-related symptoms. It can reduce amyloid burden and have benefits on mitochondrial integrity and dynamics. Many of its protective effects are mediated through steroid receptors and may also be related to neuroglobin, whose elevated levels have been shown to protect against neurological diseases. Its importance has increased exponentially due to its implication in the pathogenesis of AD. In this review, we discuss recent advances in tibolone, focusing on its mitochondrial-protective effects, and highlight how valuable this compound could be as a therapeutic alternative to mitigate the molecular pathways characteristic of AD.https://www.mdpi.com/2218-273X/13/7/1115Alzheimer’s diseasetibolonemitochondrianeuroglobinoestrogen receptors |
| spellingShingle | George E. Barreto Repurposing of Tibolone in Alzheimer’s Disease Biomolecules Alzheimer’s disease tibolone mitochondria neuroglobin oestrogen receptors |
| title | Repurposing of Tibolone in Alzheimer’s Disease |
| title_full | Repurposing of Tibolone in Alzheimer’s Disease |
| title_fullStr | Repurposing of Tibolone in Alzheimer’s Disease |
| title_full_unstemmed | Repurposing of Tibolone in Alzheimer’s Disease |
| title_short | Repurposing of Tibolone in Alzheimer’s Disease |
| title_sort | repurposing of tibolone in alzheimer s disease |
| topic | Alzheimer’s disease tibolone mitochondria neuroglobin oestrogen receptors |
| url | https://www.mdpi.com/2218-273X/13/7/1115 |
| work_keys_str_mv | AT georgeebarreto repurposingoftiboloneinalzheimersdisease |